FR2210396A1 - Blood coagulation complex - by extraction of plasma with sephadex - Google Patents

Blood coagulation complex - by extraction of plasma with sephadex

Info

Publication number
FR2210396A1
FR2210396A1 FR7245324A FR7245324A FR2210396A1 FR 2210396 A1 FR2210396 A1 FR 2210396A1 FR 7245324 A FR7245324 A FR 7245324A FR 7245324 A FR7245324 A FR 7245324A FR 2210396 A1 FR2210396 A1 FR 2210396A1
Authority
FR
France
Prior art keywords
plasma
sephadex
extraction
mixt
blood coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7245324A
Other languages
French (fr)
Other versions
FR2210396B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Cutter Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cutter Laboratories Inc filed Critical Cutter Laboratories Inc
Priority to FR7245324A priority Critical patent/FR2210396A1/en
Publication of FR2210396A1 publication Critical patent/FR2210396A1/en
Application granted granted Critical
Publication of FR2210396B1 publication Critical patent/FR2210396B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A storage stable mixt. of coagulation Factors II, VII, IX and X in non-activated form, in the same proportions as in natural human plasma and free of thrombin activated Factor X, depressor activity and anti-complement activity, is prepared by selective absorption from Effluent I, prepared by Cohn method 6 from natural human plasma, onto an ion exchanger. This ion exchanger consists of cross-linked dextran substituted by diethylaminoethyl gps. The mixt of factors is then eluted with a soln of a volatile salt. The product is used for treating coagulation disorders, e.g. for haemophilia.
FR7245324A 1972-12-19 1972-12-19 Blood coagulation complex - by extraction of plasma with sephadex Granted FR2210396A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7245324A FR2210396A1 (en) 1972-12-19 1972-12-19 Blood coagulation complex - by extraction of plasma with sephadex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7245324A FR2210396A1 (en) 1972-12-19 1972-12-19 Blood coagulation complex - by extraction of plasma with sephadex

Publications (2)

Publication Number Publication Date
FR2210396A1 true FR2210396A1 (en) 1974-07-12
FR2210396B1 FR2210396B1 (en) 1978-03-24

Family

ID=9108977

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7245324A Granted FR2210396A1 (en) 1972-12-19 1972-12-19 Blood coagulation complex - by extraction of plasma with sephadex

Country Status (1)

Country Link
FR (1) FR2210396A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239565A2 (en) * 1986-03-27 1987-09-30 Thomas Prof. Dr. Vukovich Method of separating proteins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239565A2 (en) * 1986-03-27 1987-09-30 Thomas Prof. Dr. Vukovich Method of separating proteins
EP0239565A3 (en) * 1986-03-27 1989-07-26 Thomas Prof. Dr. Vukovich Method of and apparatus for separating proteins

Also Published As

Publication number Publication date
FR2210396B1 (en) 1978-03-24

Similar Documents

Publication Publication Date Title
MY119241A (en) Medical material and process for producing the same.
ES461918A1 (en) Method of producing a blood-coagulation-promoting preparation from human blood plasma
ATE20697T1 (en) METHOD OF TREATMENT OF TOBACCO.
EP0180452A3 (en) Three-phase irradiation blood-treatment process
DE3165965D1 (en) Blood-coagulation-promoting products and methods of preparing them
ES8100763A1 (en) Prothrombin complex concentrates,preparation and application thereof
ATE83153T1 (en) COMPOSITION CONTAINING A TISSUE PLASMINOGEN ACTIVATOR.
ES8605677A1 (en) Method for the pasteurization of plasma or concentrates of blood coagulating factors II,VII, IX an X
ATE201823T1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN
JPS57206608A (en) Production of gamma-globulin for intravenous injection
FR2210396A1 (en) Blood coagulation complex - by extraction of plasma with sephadex
NL7216969A (en) Blood coagulation complex - by extraction of plasma with sephadex
ES2007429A6 (en) Foamed polymeric materials and method for preparing the same
ES412270A1 (en) Arabinofuranosyl cytosines and methods of making
ES465180A1 (en) Immunoglobulin having a reduced complement fixation, a process for its preparation and agents containing this immunoglobulin
ATE77102T1 (en) PROCESSES FOR PURIFICATION AND PASTEURIZATION OF UROKINASE.
GB1470395A (en) Composition for skin treatment
ES450299A1 (en) Amides of pyrrolidinoethylamine which can be used in treatment of coughs
FR2320756A1 (en) Treating acute orange-cerebral syndrome - with trazodone (analogues) which is(are) more effective and quicker than known treatments
GB9814039D0 (en) Materials and methods relating to the prevention or treatment of ischaemia-reperfusion injury
NL7513892A (en) Ascorbic acid medicaments for external use - as nasal decongestants and to promote resistance to infection
IE34728L (en) Treatment of migraine
El-Dib et al. Adsorption of Sevin and Baygon on powdered activated carbon.
SU1074521A1 (en) Method of obtaining material for endoprosthesing
JPS51136359A (en) Compound waste water treating material